Saturday 17 October 2026
Export PDSB’s income statement to Excel — free account
PDS Biotechnology Corporation
PDSB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 14.3%, free cash flow grew 69.3% and total debt fell 66.6%, each against the same quarter a year earlier.
1.12
0.18
−13.85%
Follow PDSB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
0.57 | 2.26 | 2.98 | 2.09 |
+8 more quarters Free account |
Net Debt/EBITDA |
0.20 | 1.82 | 1.59 | 1.69 | |
Debt/Assets |
49.19% | 43.08% | 55.39% | 34.35% | |
Debt/Equity |
(1.21) | 2.73 | 1.83 | 1.26 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.29 | 0.59 | 0.49 | 0.66 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(1.92) | (6.43) | (6.00) | (7.08) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.05) | (0.08) | (0.08) | (0.13) | |
Cash per Share |
0.10 | 0.39 | 0.58 | 0.56 | |
Shareholders Equity per Share |
(0.06) | 0.07 | 0.20 | 0.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.06) | 0.07 | 0.20 | 0.20 | |
Free Cash Flow |
(2.79) | (4.37) | (3.70) | (5.92) | |
Working Capital |
(5.33) | 12.74 | 18.77 | 14.56 | |
Net Current Asset Value |
(5.34) | 2.12 | 7.01 | 2.64 | |
| Other line items | |||||
Quick Ratio |
0.45 | 2.13 | 2.82 | 1.97 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.05) | (0.08) | (0.08) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
5.45 | 3.25 | 2.63 | 3.24 | |
Average Assets |
24.64 | 35.85 | 37.93 | 43.58 | |
Average Common Equity |
6.19 | 13.13 | 14.13 | 15.73 |
Columns are period end dates